Brief: Immuron Ltd Says Positive Results Support Travelan Progress To Phase 3 Clinical Trials In US
March 7 (Reuters) - Immuron Ltd IMC.AX :
* POSITIVE RESULTS SUPPORT TRAVELAN PROGRESS TO PHASE 3
CLINICAL
TRIALS IN US
Further company coverage: IMC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million